Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ferrara, R
Right arrow Articles by Ferrari, R
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ferrara, R
Right arrow Articles by Ferrari, R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Neurohormonal modulation in chronic heart failure

R Ferrara1, F Mastrorilli1, G Pasanisi1, S Censi1, N D'aiello1, A Fucili1, M Valgimigli1,2 and R Ferrari*,1

a Cardiovascular Research Center, `S. Maugeri'Foundation, Gussago Brescia, Italy
b Chair of Cardiology, University of Ferrara, Arcispedale S. Anna, Ferrara, Italy

* Correspondence: Professor Roberto Ferrari, Cattedra di Cardiologia, Universita' di Ferrara, H. S. Anna, UniO Operativa di Cardiologia-UTIC, C.rso Giovecca 203, 44100 Ferrara, Italy.

Abstract

During the past 50 years there have been vast improvements in the treatment of chronic heart failure (CHF). CHF was initially considered to be a cardio-renal problem - an acute disorder leading to volume expansion and oedema. Diuretics and digitalis were the only available treatments. Subsequently, CHF was considered to be the result of both myocardial dysfunction and increased tone in the pulmonary and peripheral circulations. The presence of peripheral vasoconstriction suggested that circulatory failure was an important component of the disease, and vasodilators were added to therapy. In the more recent past, experimental and clinical studies have demonstrated that CHF is also characterized by increased neurohormonal activation. This has led to the use of angiotensin-converting enzyme inhibitors, beta-blockers and spironolactone in CHF. Increased neurohormonal activity is now recognized as one of the major pathophysiological factors that contribute to the progression of CHF. Activation of neurohormonal mechanisms is only compensatory in the short term; chronic activation produces detrimental changes in the myocardirun, kidneys and peripheral vasculature. This article provides an overview of the key neurohormonal systems that are activated in CHF.

Key Words: Chronic heart failure • left ventricular dysfunction • neurohormones • ventricular remodelling


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
V. J Colucci and B. D Berry
Heart Failure Worsening and Exacerbation After Venlafaxine and Duloxetine Therapy
Ann. Pharmacother., June 1, 2008; 42(6): 882 - 887.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Ferrari
Physical training in chronic heart failure: much more than training
Eur. Heart J., December 1, 2002; 23(23): 1803 - 1804.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.